| Name | Title | Contact Details |
|---|
X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx`s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx`s innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions. IntelGenx`s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx`s state-of-the-art manufacturing facility offers full service by providing lab-scale through to pilot- and commercial-scale production.
Canada’s Global Life Sciences Venture / Partenaire d’affaires en sciences de la vie au Canada #lifesciences #biotech #sante
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications.
Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.